Back to Semax research
semax nootropic preclinical animal n preclinical 2026-04-03 PubMed

Semax peptide suppresses inflammatory proteins and activates recovery pathways after ischemic stroke in rats

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH

Background

The peptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic derivative of melanocortin used clinically for treating ischemic stroke. Previous research has established its effects at the genetic level, showing that Semax enhances the transcription of neurotrophins and their receptors. Furthermore, genome-wide RNA sequencing has revealed that in models of cerebral ischemia, Semax suppresses the expression of inflammatory genes while activating genes related to neurotransmitter function. However, the translation of these genetic changes into protein-level expression, which is the functional endpoint of gene activity, remained to be fully characterized. This study aimed to bridge that gap by investigating how Semax modulates the expression of key proteins directly involved in the cellular response to ischemic brain injury, specifically those governing inflammation, cell death, and recovery processes.

Study Design

This study utilized a rat model of transient middle cerebral artery occlusion (tMCAO) to simulate ischemic stroke. The researchers evaluated the effects of Semax administration on the brain's protein expression profile. At 24 hours post-tMCAO, they performed brain expression profiling to analyze the levels of specific proteins. The key proteins targeted were matrix metalloproteinase-9 (MMP-9), proto-oncogene c-Fos (c-Fos), and c-Jun N-terminal kinase (JNK), which are involved in inflammation and cell death. They also measured active cyclic AMP-responsive element-binding protein (CREB), a marker for neuroprotection and recovery processes. The analysis was conducted on tissues from both the ischemic core and the adjacent frontoparietal cortex.

Results

At 24 hours after inducing ischemic stroke, Semax administration led to significant changes in protein expression that confirmed its neuroprotective effects. The most notable findings include the upregulation of active CREB within the subcortical structures, which includes the primary ischemic damage zone. This suggests an activation of cellular recovery and survival mechanisms directly at the site of injury.

Concurrently, Semax produced a notable downregulation of MMP-9 and c-Fos in the frontoparietal cortex adjacent to the stroke focus. This indicates a reduction in inflammation and potentially harmful cellular stress responses in the surrounding, vulnerable brain tissue.

Furthermore, the study observed a downregulation of active JNK in both the ischemic core and the adjacent cortex, pointing to a broad suppression of a key cell death signaling pathway. Based on these protein expression changes, the researchers constructed a regulatory network, concluding that Semax exerts its protective effects by simultaneously suppressing inflammatory/cell death pathways and activating recovery pathways at both the transcriptome and protein levels, providing a more complete picture of its mechanism of action.

Key Findings

  • At 24h post-stroke, Semax upregulated active CREB in subcortical structures, including the ischemic core.
  • Semax downregulated MMP-9 and c-Fos in the frontoparietal cortex adjacent to the ischemic lesion.
  • The peptide downregulated active JNK, a cell death-associated protein, in both the ischemic core and adjacent cortex.
  • The study confirms that Semax's neuroprotective action occurs at both the transcriptome and protein levels.
  • Semax suppresses inflammatory and cell death processes while activating recovery pathways.

Why It Matters

This research reinforces the molecular basis for Semax's use in ischemic stroke, moving beyond genetic transcription to confirm its effects on functional protein expression. For individuals exploring nootropics or neuroprotective agents, this provides evidence that Semax's benefits are not just theoretical but are manifested through the modulation of concrete cellular machinery involved in brain repair. The findings suggest that Semax actively suppresses the damaging inflammatory cascade (MMP-9, JNK) while simultaneously boosting the brain's own recovery systems (CREB). This dual action makes it a compelling agent for post-stroke recovery protocols. While this is an animal study, it validates the multi-pronged mechanism of Semax, suggesting its potential role is not just in mitigating initial damage but also in promoting long-term neural repair. Further clinical investigation is needed to translate these protein-level insights into optimized human dosing and timing strategies for stroke rehabilitation.

TitrateLab articles covering Semax

Written by TitrateLab, separately from the study summarized above.


semax nootropic melanocortin semax stroke ischemic stroke neuroprotection animal study neurological
Source: pubmed:34201112 · Ingested Apr 3, 2026 · Digest: gemini-2.5-pro